Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein

Thrombosis Research

Volumn 116, Issue 3, 2005, Pages 255-263

  Radha, K S ^a   Sugiki, Masahiko ^a   Yoshida, Etsuo ^a   Kumar, M Harish ^a   Omura, Sayuri ^a   Maruyama, Masugi ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Iron deprivation; mRNA binding protein; mRNA stability; PAI 1; Post transcriptional regulation

Indexed keywords

BINDING PROTEIN; DEFEROXAMINE; FERRIC CITRATE; IRON; MESSENGER RNA; NUCLEAR PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADENOCARCINOMA; ARTICLE; BINDING AFFINITY; CARCINOMA CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IRON DEPLETION; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; RNA STABILITY;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; CELL LINE, TUMOR; DEFEROXAMINE; FERRIC COMPOUNDS; HUMANS; IRON; IRON CHELATING AGENTS; NUCLEAR PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA STABILITY; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 20144380188     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.12.006     Document Type: Article

References (43)

1. J.P. Irigoyen, P. Munoz-Canoves, L. Montero, M. Koziczak, and Y. Nagamine The plasminogen activator system: biology and regulation Cell. Mol. Life Sci. 56 1-2 1999 104 132
2. M.S. Pepper Extracellular proteolysis and angiogenesis Thromb. Haemost. 86 1 2001 346 355
3. P.A. Andreasen, L. Kjoller, L. Christensen, and M.J. Duffy The urokinase-type plasminogen activator system in cancer metastasis: a review Int. J. Cancer 72 1 1997 1 22
4. G. Liu, M.A. Shuman, and R.L. Cohen Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells Int. J. Cancer 60 4 1995 501 506
5. M. Cazzola, G. Bergamaschi, L. Dezza, and P. Arosio Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects Blood 75 10 1990 1903 1919
6. D.R. Richardson Iron chelators as therapeutic agents for the treatment of cancer Crit. Rev. Oncol./Hematol. 42 3 2002 267 281
7. T. Simonart, J.R. Boelaert, R. Mosselmans, G. Andrei, J.C. Noel, and E. De Clercq Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells Gynecol. Oncol. 85 1 2002 95 102
8. P.J. Bosma, and T. Kooistra Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells J. Biol. Chem. 266 27 1991 17845 17849
9. M. Sandler, J. Zhang, D. Westerhausen Jr., and J. Billadello A novel protein interacts with the major transforming growth factor-beta responsive element in the plasminogen activator inhibitor type-1 gene J. Biol. Chem. 269 34 1994 21500 21504
10. N. Montuori, G. Rossi, and P. Ragno Post-transcriptional regulation of gene expression in the plasminogen activation system Biol. Chem. 383 1 2002 47 53
11. S. Shetty, and S. Idell Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro Am. J. Physiol., Lung Cell. Mol. Physiol. 278 1 2000 L148 L156
12. J.H. Heaton, W.M. Dlakic, M. Dlakic, and T.D. Gelehrter Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the type-1 plasminogen activator inhibitor mRNA J. Biol. Chem. 276 5 2001 3341 3347
13. T. Hasegawa, L. Sorensen, H. Ooi, and B.C. Marshall Decreased intracellular iron availability suppresses epithelial cell surface plasmin generation. Transcriptional and post-transcriptional effects on u-PA and PAI-1 expression Am. J. Respir. Cell Mol. Biol. 21 2 1999 275 282
14. L.C. Yeh, V. Mikhailov, and J.C. Lee Regulation of expression of plasminogen activator inhibitor-1 in cultured rat osteoblastic cells by osteogenic protein-1 (BMP-7) J. Cell. Biochem. 81 S36 2001 46 54
15. J.D. Dignam, P.L. Martin, B.S. Shastry, and R.G. Roeder Eukaryotic gene transcription with purified components Methods Enzymol. 101 1983 582 598
16. G.A. Soff, J. Sanderowitz, S. Gately, E. Verrusio, I. Weiss, and S. Brem Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model J. Clin. Invest. 96 6 1995 2593 2600
17. G.A. McMahon, E. Petitclerc, S. Stefansson, E. Smith, M.K.K. Wong, and R.J. Westrick Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis J. Biol. Chem. 276 36 2001 33964 33968
18. K. Bajou, V. Masson, R.D. Gerard, P.M. Schmitt, V. Albert, and M. Praus The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies J. Cell Biol. 152 4 2001 777 784
19. C. Isogai, W.E. Laug, H. Shimada, P.J. Declerck, M.F. Stins, and D.L. Durden Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin Cancer Res. 61 14 2001 5587 5594
20. S. Stefansson, G.A. McMahon, E. Petitclerc, and D.A. Lawrence Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling Curr. Pharm. Des. 9 19 2003 1545 1564
21. T.D. Brooks, J. Slomp, P.H. Quax, A.C. De Bart, M.T. Spencer, and J.H. Verheijen Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro Clin. Exp. Metastasis 18 6 2000 445 453
22. M.P. Ryan, S.M. Kutz, and P.J. Higgins Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion Biochem. J. 314 Pt3 1996 1041 1046
23. J. Arts, J. Grimbergen, K. Toet, and T. Kooistra On the role of c-Jun in the induction of PAI-1 gene expression by phorbol ester, serum, and IL-1{alpha} in HepG2 Cells Arterioscler. Thromb. Vasc. Biol. 19 1 1999 39 46
24. I. Tamm, and P.B. Sehgal Halobenzimidazole ribosides and RNA synthesis of cells and viruses Adv. Virus Res. 22 1978 187 258
25. L.R. Lund Expression of urokinase-type plasminogen activator, its receptor and type-1 plasminogen activator inhibitor is differently regulated by inhibitors of protein synthesis in human cancer cell lines FEBS Lett. 383 3 1996 139 144
26. G. Shaw, and R. Kamen A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation Cell 46 5 1986 659 667
27. M.S. Altus, and Y. Nagamine Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA. Studies in vivo and in cell-free decay reactions J. Biol. Chem. 266 31 1991 21190 21196
28. Q. Zhang, Y. Wu, D.K. Ann, D.V. Messadi, T.L. Tuan, and A.P. Kelly Mechanisms of hypoxic regulation of plasminogen activator inhibitor-1 gene expression in keloid fibroblasts J. Invest. Dermatol. 121 5 2003 1005 1012
29. D. Ginsburg, R. Zeheb, A.Y. Yang, U.M. Rafferty, P.A. Andreasen, and L. Nielsen cDNA cloning of human plasminogen activator-inhibitor from endothelial cells J. Clin. Invest. 78 6 1986 1673 1680
30. J. Ross mRNA stability in mammalian cells Microbiol. Rev. 59 3 1995 423 450
31. L.R. Lund, J. Eriksen, E. Ralfkiaer, and J. Romer Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester J. Invest. Dermatol. 106 4 1996 622 630
32. P. Fattal, D. Schneider, B. Sobel, and J. Billadello Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1 J. Biol. Chem. 267 18 1992 12412 12415
33. S.C. Shih, and K.P. Claffey Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L J. Biol. Chem. 274 3 1999 1359 1365
34. R.D. Klausner, and J.B. Harford Cis-trans models for post-transcriptional gene regulation Science 246 1989 870 872
35. J.L. Casey, M.W. Hentze, D.M. Koeller, S.W. Caughman, T.A. Rouault, and R.D. Klausner Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation Science 240 4854 1988 924 928
36. S. Shetty Cytoplasmic-nuclear shuttling of the urokinase mRNA binding protein regulates message stability Mol. Cell. Biochem. 237 1-2 2002 55 67
37. S. Shetty, and S. Idell Post-transcriptional regulation of urokinase mRNA. Identification of a novel urokinase mRNA-binding protein in human lung epithelial cells in vitro J. Biol. Chem. 275 18 2000 13771 13779
38. E.A. Leibold, and H.N. Munro Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5′ untranslated region of ferritin heavy- and light-subunit mRNAs Proc. Natl. Acad. Sci. U. S. A. 85 7 1988 2171 2175
39. L.E. Rajagopalan, C.J. Westmark, J.A. Jarzembowski, and J.S. Malter hnRNP C increases amyloid precursor protein (APP) production by stabilizing APP mRNA Nucleic Acids Res. 26 14 1998 3418 3423
40. S.H. Zaidi, and J.S. Malter Nucleolin and heterogeneous nuclear ribonucleoprotein C proteins specifically interact with the 3′- untranslated region of amyloid protein precursor mRNA J. Biol. Chem. 270 29 1995 17292 17298
41. M. Kiledjian, C.T. DeMaria, G. Brewer, and K. Novick Identification of AUF1 (heterogeneous nuclear ribonucleoprotein D) as a component of the alpha-globin mRNA stability complex Mol. Cell. Biol. 17 8 1997 4870 4876
42. T. Uchiyama, M. Kurabayashi, Y. Ohyama, T. Utsugi, N. Akuzawa, and M. Sato Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells Arterioscler. Thromb. Vasc. Biol. 20 4 2000 1155 1161
43. T. Fink, A. Kazlauskas, L. Poellinger, P. Ebbesen, and V. Zachar Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1 Blood 99 6 2002 2077 2083